Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, Carla Truyers et al.|The Lancet Infectious Diseases|2022Cited by 88
Utility of polygenic embryo screening for disease depends on the selection strategyTodd Lencz, Shai Carmi, Einat Granot‐Hershkovitz et al.|eLife|2021Cited by 74